May 8, 2025

Research Triangle Park, N.C.– MAY 8, 2025 – AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 15 presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which takes place May 13–17, 2025, in New Orleans, Louisiana, USA. The company’s oral and poster presentations will provide updates on key research and development activities in gene therapy and gene editing, as well as advancements in manufacturing capabilities. Featured oral presentations will include “AI Use for Promoter and Transgene Design.” This will be delivered by Mansuo Shannon, Chief Scientific Officer at AskBio, as part of the Novel Approaches to Overcome Limits of Therapeutic Transgene Delivery and Durability scientific session. The presentation will explore how AI/ML (Artificial Intelligence/Machine Learning) may enhance efficacy, safety, and specificity of gene therapies by potentially predicting the best possible genetic sequences for the intended therapeutic outcome. In addition, AskBio’s Srinethe Saravanakumar will present “Vector Assembly Factories in Recombinant Adeno-Associated Virus Type 2 Producing Cells” as part of the AAV Biology and Mechanism session. The presentation will provide an in-depth visualization of rAAV2 (recombinant adeno-associated virus type 2) capsid assembly using electron tomography. It will also explore the potential effects of subcellular retargeting/expansion of capsid assembly through selected AAP (assembly-activating proteins) in vector production. The company’s third oral, “A Rock in a Storm: Using Data as Your Foundation to Speed and De-risk AAV Manufacturing,” will be presented by Viralgen’s María Iglesias González as part of the Tools and Technology session. This will explore how a data-led approach has the potential to significantly reduce variability, prevent costly failures, and shorten timelines from R&D to commercial production by enabling better process understanding, predictive modeling, real-time monitoring, and quality control across the development lifecycle. “Our scientific contribution to ASGCT this year underscores our long-standing commitment to advancing gene therapy research and providing leadership within the scientific community,” said Gustavo Pesquin, Chief Executive Officer, AskBio. “We are sharing updates from our early-stage programs and highlighting how we are adopting innovative approaches in our development work with the use of digitalization and AI. Equally important, we are also showcasing the work being done to advance our manufacturing processes as we continue to strengthen our end-to-end platform capabilities.” AskBio continues to develop an ambitious portfolio of investigational AAV-based gene therapies to treat some of the world’s most serious diseases, including congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease. By targeting these therapy areas, AskBio aims to deliver breakthrough treatments that could benefit tens of millions of patients worldwide.1–6 AskBio’s presentations at ASGCT include (all times CDT): Orals Posters About AskBio  AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular, and metabolic disease indications with a clinical-stage pipeline that ...read the news